1166819-53-9 Usage
Chemical class
Hetrocyclic compound
Explanation
Different sources of media describe the Explanation of 1166819-53-9 differently. You can refer to the following data:
1. It belongs to the class of triazolopyridines, which are heterocyclic compounds.
2. The compound has a triazole ring fused to a pyridine ring, forming a unique structure.
3. The molecule contains a bromo (Br) and a trifluoromethyl (CF3) group, which contribute to its chemical reactivity.
4. The presence of the bromo and trifluoromethyl groups increases the chemical reactivity of the compound, making it more versatile for various applications.
5. The compound may be used as a building block for the synthesis of biologically active molecules in pharmaceutical research or as a ligand in coordination chemistry.
6. The unique structure and properties of 1,2,4-Triazolo[4,3-a]pyridine, 6-broMo-3-(trifluoroMethyl)make it a valuable tool for researchers in the fields of chemistry and medicine.
Structure
Triazole ring fused to a pyridine ring
Presence of functional groups
Bromo and trifluoromethyl groups
Chemical reactivity
Enhanced due to functional groups
Potential applications
Pharmaceutical research and coordination chemistry
Research value
Valuable tool for chemical and medicinal research
Check Digit Verification of cas no
The CAS Registry Mumber 1166819-53-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,6,8,1 and 9 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1166819-53:
(9*1)+(8*1)+(7*6)+(6*6)+(5*8)+(4*1)+(3*9)+(2*5)+(1*3)=179
179 % 10 = 9
So 1166819-53-9 is a valid CAS Registry Number.
1166819-53-9Relevant articles and documents
FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
-
Page/Page column 32, (2011/02/18)
The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
